Metastatic Non Small Cell Lung Cancer Clinical Trial
Official title:
A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
LN-145 is a ready-to-infuse TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study involves patients receiving a non-myeloablative (NMA) lymphodepleting preparative regimen, followed by infusion of autologous TIL, then finally followed by the administration of IL-2. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04965090 -
A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Recruiting |
NCT06060613 -
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04884282 -
Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
|
Phase 2 | |
| Recruiting |
NCT05236608 -
A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05215340 -
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
|
Phase 3 | |
| Withdrawn |
NCT06068153 -
AMG510 (Sotorasib) Plus Lenvatinib as Second-line Treatment in Patients With KRASG12C Mutant, Metastatic NSCLC
|
Phase 2 | |
| Not yet recruiting |
NCT06066138 -
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
|
Phase 1 | |
| Recruiting |
NCT05429320 -
A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
| Recruiting |
NCT05478538 -
Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
|
||
| Completed |
NCT01773109 -
Etirinotecan Pegol (NKTR-102) in NSCLC
|
Phase 2 | |
| Recruiting |
NCT04743505 -
Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05111197 -
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy
|
Phase 3 | |
| Recruiting |
NCT05555732 -
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
|
Phase 3 | |
| Recruiting |
NCT05676749 -
C-TIL051 in Non-Small Cell Lung Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT05566223 -
CISH Inactivated TILs in the Treatment of NSCLC
|
Phase 1/Phase 2 | |
| Terminated |
NCT01060514 -
Pazopanib + Vinorelbine in Non Small Cell Lung Cancer (NSCLC) and Breast Cancer
|
Phase 1 | |
| Completed |
NCT05167500 -
Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment
|
||
| Recruiting |
NCT05259319 -
Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)
|
Phase 1 | |
| Enrolling by invitation |
NCT04697446 -
External Control, Observational, Retrospective Study Comparing Pralsetinib to Best Available Therapy in Patients With RET-Fusion Positive NSCLC
|
||
| Completed |
NCT04511533 -
Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations
|
Phase 4 |